- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Andexanet Alfa effectively controls acute major bleeding due to Factor Xa Inhibitors
![Andexanet Alfa effectively controls acute major bleeding due to Factor Xa Inhibitors Andexanet Alfa effectively controls acute major bleeding due to Factor Xa Inhibitors](https://medicaldialogues.in/h-upload/2022/04/23/750x450_174882-blood-test.webp)
A recent study published in the Circulation Journal found andexanet alfa effective in reversing the effects of Factor Xa Inhibitors and achieving hemostasis in patients with acute major bleeding.
Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse Factor Xa Inhibitors. A phase-3b/4, multicenter, prospective, single-group cohort study (ANNEXA-4) by Truman Milling Jr and peers carefully evaluated the efficacy and safety of andexanet alfa in patients with acute major bleeding within 18 hours of FXa inhibitor administration.
The study included 479 patients with bleeding predominantly in the intracranial or gastrointestinal areas. The co-primary endpoints were anti-FXa activity change from baseline during andexanet alfa treatment and excellent or good hemostatic efficacy at 12 hours. The efficacy population included patients with baseline anti-FXa activity levels above predefined thresholds who met the major bleeding criteria, and the safety population included all patients.
The key highlights of the study were:
Andexanet alfa reduced anti-FXa activity in patients treated with apixaban, rivaroxaban, edoxaban, and enoxaparin by 93%, 94%, 71%, and 75%, respectively.
Excellent or good hemostasis occurred in 80% of patients with major bleeding.
Thrombotic events occurred in 10% of patients in the safety population, with no thrombotic episodes occurring after oral anticoagulation restart. Median endogenous thrombin potential was within the normal range by the end of andexanet alfa bolus through 24 hours for all FXa inhibitors.
The study supports the use of andexanet alfa as a safe and effective antidote for FXa inhibitors in patients with acute major bleeding.
Source:
Milling, T. J., Jr, Middeldorp, S., Xu, L., Koch, B., Demchuk, A., Eikelboom, J. W., Verhamme, P., Cohen, A. T., Beyer-Westendorf, J., Michael Gibson, C., Lopez-Sendon, J., Crowther, M., Shoamanesh, A., Coppens, M., Schmidt, J., Albaladejo, P., Connolly, S. J., Anand, R., Bastani, A., … Demchuk, A. M. (2023). Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. In Circulation. Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1161/circulationaha.121.057844.
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751